Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

950
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
950
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

754
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
754
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

877
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
877
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease.

Clinical kidney journal·2020
Same author

Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

Journal of the American Heart Association·2020
Same author

Funding kidney research as a public health priority: challenges and opportunities.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2020
Same author

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

The New England journal of medicine·2020
Same author

Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus.

Scientific reports·2020
Same author

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.

International journal of molecular sciences·2020

Related Experiment Video

Updated: Apr 12, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K

Fabry disease and the heart.

Nora Seydelmann1, Christoph Wanner2, Stefan Störk2

  • 1Department of Medicine, University Hospital, Wuerzburg, Germany.

Best Practice & Research. Clinical Endocrinology & Metabolism
|May 20, 2015
PubMed
Summary

Fabry disease, caused by alpha-galactosidase A deficiency, leads to cardiac issues like hypertrophy and fibrosis. Early enzyme replacement therapy can improve Fabry cardiomyopathy outcomes.

Keywords:
Fabry diseasecardiomyopathymonitoringtreatment

More Related Videos

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts
07:10

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts

Published on: May 16, 2021

5.5K
Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K
Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts
07:10

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts

Published on: May 16, 2021

5.5K
Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.8K

Area of Science:

  • Genetics and Molecular Biology
  • Cardiology
  • Rare Diseases

Background:

  • Fabry disease results from alpha-galactosidase A gene mutations, leading to enzyme deficiency and globotriaosylceramide accumulation.
  • This accumulation affects multiple organs, notably the heart, causing left ventricular hypertrophy and progressive myocardial fibrosis.
  • Cardiac involvement is a significant manifestation, impacting disease progression and patient prognosis.

Purpose of the Study:

  • To provide a comprehensive overview of Fabry disease.
  • To focus on the cardiac manifestations of Fabry disease, including characteristic features and clinical presentation.
  • To discuss the current treatment options for Fabry disease, particularly enzyme replacement therapy.

Main Methods:

  • Literature review of Fabry disease, focusing on cardiac involvement.
  • Analysis of clinical presentation, pathological features, and diagnostic criteria.
  • Evaluation of the efficacy and timing of enzyme replacement therapy.

Main Results:

  • Fabry cardiomyopathy is characterized by concentric left ventricular hypertrophy and myocardial fibrosis.
  • Early enzyme replacement therapy (ERT) can improve cardiac morphology, function, and exercise capacity.
  • ERT may halt disease progression in end-stage cardiomyopathy, though fibrosis development impacts outcomes.

Conclusions:

  • Fabry disease requires early diagnosis and intervention, especially regarding cardiac complications.
  • Enzyme replacement therapy is effective in managing Fabry cardiomyopathy if initiated before significant fibrosis occurs.
  • Continued research and timely treatment are crucial for improving the long-term outlook for patients with Fabry disease.